Clinical Trial Update: Velcade (Bortezomib) Consolidation After Transplant [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Velcade (bortezomib) as consolidation after transplant in multiple myeloma. The study is completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2017-02-09